CD274 and non-small cell lung carcinoma: In a phase 3 trial evaluating the efficacy of pembrolizumab (KEYNOTE-010 trial), the 5-year OS and PFS rates were 25.0% and 18.2% in previously treated patients with NSCLC with PD-L1 TPS greater than or equal to 50% and were 15.6% and 9.4% in patients with PD-L1 TPS greater than or equal to 1%, respectively, suggesting a positive correlation between PD-L1 expression, PFS, and OS.3